Prescription Drug Price Transparency
Drugs of Substantial Public Interest Lists

The Minnesota Legislature expanded the Minnesota Prescription Drug Price Transparency Act (Minnesota Statutes 62J.84) in 2023 to include reporting from drug manufacturers, pharmacy benefit managers, wholesalers, and pharmacies on drugs of substantial public interest. The Minnesota Department of Health (MDH) is responsible for producing and publicly posting lists of the prescription drugs requiring reporting.

For each reporting cycle, MDH releases the list of drugs, which establishes the reporting requirement for the cycle, and notifies reporting entities 30 or more days after posting the list. From the date of notification, reporting entities have a 60-day submission window during which the required data must be submitted.

MDH invites your ideas or suggestions for prescription drugs on which to collect data. Visit the Public Input page for information on how to provide input.

Current & Recent Lists

• March 2025—Insulin

  • List: March 2025 - Insulin: List of Drugs of Substantial Public Interest (Excel)

  • Methodology: March 2025 - Insulin: List Methodology for Drugs of Substantial Public Interest Reporting (PDF)

• June 2024—Generic Markups

  • List: June 2024 - Generic Markups: List of Drugs of Substantial Public Interest (Excel)

  • Methodology: June 2024 - Generic Markups: List Methodology for Drugs of Substantial Public Interest Reporting (PDF)